Stay updated with breaking news from Katz Professor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cholesterol Efflux Mediator™VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular...
Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including diabetic
PHILADELPHIA — The question of who should take aspirin is a complicated one and public messaging on it is sometimes confusing, a speaker said at the Heart in Diabetes CME conference. Laurence S. Sperling, MD, FACC, FACP, FAHA, FASPC, Katz Professor in Preventive Cardiology and professor of global health at Emory University and executive director of the Million Hearts initiative, said
Here’s a look at business news in our community.
Endocrine Today | About 25% of U.S. adults have nonalcoholic fatty liver disease, which is the most common chronic liver condition in the U.S., according to the American Liver Foundation. Nonalcoholic fatty liver disease, known as NAFLD, can progress to nonalcoholic steatohepatitis (NASH), which is a leading indication for liver transplant. However, most patients with NAFLD die of cardiovascular disease, not liver